MedAvail Holdings, Inc (MDVL)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W

15.63+0.30 (+1.96%)

At close: 4:00PM EST

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Price Crosses Moving Average

View all chart patterns

Performance Outlook

Previous Close	15.33
Open	15.13
Bid	8.00 x 1000
Ask	16.15 x 800
Day's Range	15.04 - 16.05
52 Week Range	8.89 - 46.20
Volume	72,975
Avg. Volume	108,971

Market Cap	494.985M
Beta (5Y Monthly)	N/A
PE Ratio (TTM)	N/A
EPS (TTM)	N/A
Earnings Date	Nov 06, 2020
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	18.50

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

Research Reports

Business Wire
TMCOne Continues to Expand Relationship with MedAvail, Offering Integrated In-Clinic Pharmacy Experience in Multiple Locations
MedAvail Holdings, Inc. (Nasdaq: MDVL) ("MedAvail"), a technology-enabled retail pharmacy company, today announced that TMCOne has continued to expand its relationship with MedAvail with the opening of its third clinic with an embedded SpotRx MedCenter. SpotRx Pharmacy is the retail pharmacy brand owned and operated by MedAvail in the United States, which deploys and operates the MedAvail MedCenters.
- Fairview Pharmacy Service Receives URAC Rare Disease Designation
  GlobeNewswire
- Local pharmacies say they need more COVID-19 vaccines as CVS, Walgreens ramp up shots
  USA TODAY
PR Newswire
MYOS CORP Secures Fourth Patent as Part of R&D Drive to Address Healthcare Burden of Sarcopenia and Muscle-Related Disorders
MYOS CORP ("MYOS" or the "Company"), a research-based advanced nutrition company with divisions that address both Human Nutrition and Animal Health, announced today that it has been granted United States Patent #10,925,904 by the United States Patent and Trademark Office (USPTO). The new patent, titled "Methods and Compositions for Improving Skeletal Muscle Protein Fractional Synthetic Rate," protects advanced technologies related to improving skeletal muscle protein synthetic rate in older mammals through the administration of proprietary nutritional compositions such as MYOS' advanced nutrition product, Fortetropin®.
Simply Wall St.
MedAvail Holdings, Inc's (NASDAQ:MDVL) Intrinsic Value Is Potentially 48% Above Its Share Price
Today we will run through one way of estimating the intrinsic value of MedAvail Holdings, Inc ( NASDAQ:MDVL ) by taking...